Table 1.
Baseline characteristics
| Tirofiban (%) ¶ | Placebo (%) Ω | p | |
|---|---|---|---|
| Patients | 24 (41.4%) | 34 (58.6%) | |
| Age | 59.5 (±10.5) | 58.3 (±11.9) | (=0.70) Ţ |
| Male | 19 (79.2%) | 30 (88.2%) | (=0.46) ƒ |
| Caucasian | 22 (91.6%) | 27 (79.4%) | (=0.28) ƒ |
| BMI ≥ 30 | 5 (20.8 %) | 7 (20.6%) | (=1.00) ƒ |
| Hypertension | 16 (66.6%) | 23 (67.6%) | (=0.84) χ |
| Smokers | 13 (54.2%) | 16 (47.1%) | (=0.79) χ |
| Dyslipidemia | 10 (41.6%) | 11 (32.4%) | (=0.58) χ |
| CAD Family History | 5 (20.8%) | 12 (35.3%) | (=0.26) ƒ |
| Diabetes | 3 (12.5%) | 7 (20.6%) | (=0.49) ƒ |
| ACEI/ARB | 10 (41.6%) | 15 (44.1%) | (=1.00) ƒ |
| Oral antidiabetic | 3 (12.5%) | 8 (23.5%) | (=0.33) ƒ |
| Statin | 6 (25%) | 3 (8.8%) | (=0.14) ƒ |
| ASA | 2 (8.3%) | 4 (11.7%) | (=1.00) ƒ |
| Diuretics | 1 (4.2%) | 5 (14.7%) | (=0.38) ƒ |
BMI: body mass index; CAD: coronary artery disease; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; ASA: acetylsalicylic acid; p: p-value;
ƒ
p-value calculated by Fisher Exact Test;
Ţ
p-value calculated by “t” Student Test (95% IC 4.86-7.26);
Χ
p-value calculated by Chi-square Test;
¶
tirofiban percentage group;
Ω
placebo percentage group